Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
This video was recorded during the American Heart Association’s Scientific Sessions 2022 in Chicago, IL, USA.
David Preiss, PhD - Associate Profesor and Honorary Consultant in Metabolic Medicine, MRC Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, UK.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: